Thursday 16 October, 2025
Objectives: Sleep structure recorded in a laboratory is distorted, particularly during the first night [1]. This phenomenon, called First Night…
Read morePoster: Other topics - Applications
Longitudinal model-based meta-analysis in rheumatoid arthritis: an application towards model based drug development
Thursday 16 October, 2025
Objectives: The aim was two-fold, first to quantify the longitudinal behavior of the key clinical measure of signs and symptomes…
Read moreA Population Pharmacokinetic/pharmacodynamic Approache of Drug X in Healthy Korean
Thursday 16 October, 2025
Objectives: Drug X is a selective arginine vasopressin (AVP) V2-receptor antagonist which is used for treatment of acute and chronic…
Read morePopulation PK/PD evaluation of the effect of dienogest on Hoogland Score in young healthy women
Thursday 16 October, 2025
Objectives: Dienogest (DNG) is a 19-nortestosterone derivative that exhibits selective binding to the progesterone receptor and displays neither agonist nor…
Read moreDevelopment of a Bayesian forecasting method for warfarin dose individualisation
Thursday 16 October, 2025
Objectives: Warfarin is the most commonly prescribed oral anticoagulant worldwide. It is a difficult drug to dose accurately due to…
Read moreA population pharmacokinetic model for Gd-DTPA in DCE-MRI
Thursday 16 October, 2025
Objectives: In dynamic contrast enhanced magnetic resonance imaging (DCE-MRI), the kinetics of an injected contrast agent (Gd-DTPA) can be simultaneously…
Read moreEvaluation of Circadian Rhythms in Hepatic CYP3A4 Activity Using Population Pharmacokinetics of Midazolam
Thursday 16 October, 2025
Objectives: Chronopharmacology deals with the impact of circadian rhythms on the pharmacokinetics and pharmacodynamics of different drugs. Diurnal changes in…
Read morePopulation PK/PD Modeling of a Hepatitis C NS3 Inhibitor
Thursday 16 October, 2025
Objectives: ACH-0141625, currently in development for treatment of HCV infection, is a potent inhibitor of HCV NS3 protease suited for once…
Read moreDiversity: Academia-Industry Collaborations on Modeling and Simulation to enhance Scientific Capability Development – The Novartis Experience
Thursday 16 October, 2025
Objectives: Academic and industry collaboration for the advancement of science has a long history and track record of success. We…
Read moreTarget Mediated Drug Disposition Model to Describe the Expression and Kinetics of IL12 And IFNγ in Gene Therapy
Thursday 16 October, 2025
Objectives: Interleukin-12 (IL12) has shown to have a great therapeutical potential in the treatment of chronic hepatic diseases [1]. Nevertheless…
Read more